An alternative explanation for the increased risk observed in the French study, emerging early and staying at similar magnitude with increasing duration of use, could be detection bias.17 Our additional analysis indicated a nominally increased risk restricted to the first year after starting treatment, which might be consistent with an increased detection of thyroid cancer among patients using GLP1 receptor agonists. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.